Imagine a disease that twists and contorts, leaving its victims in agony. This is the reality of Chikungunya, a virus that has been silently wreaking havoc in East Africa, while the world focused on Zika.
In 2016, Zika dominated global headlines as the virus spread rapidly through Brazil, causing alarm when linked to severe birth defects. But in Kenya's Kilifi county, a similar crisis was unfolding. Prof. George Warimwe, a local investigator, initially suspected Zika, but tests revealed a different culprit: Chikungunya.
Chikungunya, named after the Makonde word for 'to become contorted', causes fever and excruciating joint pain, sometimes lasting for years. It was first identified in Tanzania in 1952 and has since been a hidden menace. Warimwe's team found that 10% of children hospitalized with neurological illness in Kilifi were infected with Chikungunya, some just weeks old, indicating in-utero transmission.
But here's where it gets controversial: while Zika received global attention, Chikungunya's impact in Kenya went largely unnoticed. Now, Kenya is fighting back with enhanced surveillance, and over 600 cases have been reported this year alone.
The global picture is alarming. Nearly 500,000 infections have been reported in 2023, with hotspots in Brazil and India, and new cases emerging in China, New York, and Paris. Travel-related cases are also on the rise in Europe.
The challenge lies in accurate diagnosis. Chikungunya symptoms mimic malaria and dengue, leading to frequent misdiagnoses. Moreover, the full spectrum of symptoms is not yet fully understood, and diagnostic tools are lacking.
Enter the ACHIEVE study, a $10.3 million initiative funded by CEPI, led by Warimwe. This program aims to train medical staff in Kenya and Tanzania to screen patients with fever or neurological symptoms for Chikungunya. The goal is early detection, better care, and tracking the virus's spread.
ACHIEVE will also investigate the impact of Chikungunya on pregnant women and mother-to-child transmission. This data is crucial for vaccine development and distribution strategies, ensuring protection for those most vulnerable.
The study will explore various aspects, including different virus strains, economic impact, and immune responses. By studying patients over two years, researchers can understand Chikungunya's behavior and how climate change influences its spread.
"The warming climate creates an ideal environment for infected mosquitoes to thrive," says Breugelmans from CEPI. "We must stay vigilant as Chikungunya hotspots evolve." The ACHIEVE team is dedicated to gathering data to alleviate the suffering caused by this debilitating disease.
With the involvement of renowned institutions like Oxford University and the Kenya Medical Research Institute, the study aims to provide critical insights into Chikungunya's burden in East Africa and guide effective interventions.
